Journal
PHARMACEUTICS
Volume 14, Issue 1, Pages -Publisher
MDPI
DOI: 10.3390/pharmaceutics14010200
Keywords
TGF beta-signaling; neurogenesis; neurodegeneration; amyotrophic lateral sclerosis; GLP-ToxStudy; antisense oligonucleotide therapy; LNA
Categories
Funding
- German Federal Ministry of Education and Research (BMBF) [031A386]
- German Ministry of Economics and Energy (BMWI) [KF2525608MD3]
- Bavarian Ministry of Economics, Energy and Infrastructure (PTJ) [BIO-1506-0002]
Ask authors/readers for more resources
Through the study of the pharmacology, safety, and tolerability of LNA Gapmer Antisense Oligonucleotide NVP-13 in nonhuman primates, we found that it effectively reduces the expression of TGFBR2, decreases TGF beta signal transduction, and enhances neurogenic niche activity. The use of NVP-13 in cynomolgus monkeys did not result in any adverse events.
The capability of the adult central nervous system to self-repair/regenerate was demonstrated repeatedly throughout the last decades but remains in debate. Reduced neurogenic niche activity paralleled by a profound neuronal loss represents fundamental hallmarks in the disease course of neurodegenerative disorders. We and others have demonstrated the endogenous TGF beta system to represent a potential pathogenic participant in disease progression, of amyotrophic lateral sclerosis (ALS) in particular, by generating and promoting a disequilibrium of neurodegenerative and neuroregenerative processes. The novel human/primate specific LNA Gapmer Antisense Oligonucleotide NVP-13 , targeting TGFBR2, effectively reduced its expression and lowered TGF beta signal transduction in vitro and in vivo, paralleled by boosting neurogenic niche activity in human neuronal progenitor cells and nonhuman primate central nervous system. Here, we investigated NVP-13 in vivo pharmacology, safety, and tolerability following repeated intrathecal injections in nonhuman primate cynomolgus monkeys for 13 weeks in a GLP-toxicology study approach. NVP-13 was administered intrathecally with 1, 2, or 4 mg NVP-13/animal within 3 months on days 1, 15, 29, 43, 57, 71, and 85 in the initial 13 weeks. We were able to demonstrate an excellent local and systemic tolerability, and no adverse events in physiological, hematological, clinical chemistry, and microscopic findings in female and male Cynomolgus Monkeys. Under the conditions of this study, the no observed adverse effect level (NOAEL) is at least 4 mg/animal NVP-13.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available